.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

TRICOR Drug Profile

« Back to Dashboard
Tricor is a drug marketed by Abbott and Abbvie and is included in three NDAs. It is available from eleven suppliers. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-five patent family members in forty-two countries.

The generic ingredient in TRICOR is fenofibrate. There are forty-one drug master file entries for this compound. Forty-six suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the fenofibrate profile page.

Summary for Tradename: TRICOR

Patents:9
Applicants:2
NDAs:3
Suppliers / Packagers: see list11
Drug Prices: :see details

Pharmacology for Tradename: TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
TRICOR (MICRONIZED)
fenofibrate
CAPSULE;ORAL019304-003Jun 30, 1999DISCNNo► subscribe► subscribe
Abbvie
TRICOR (MICRONIZED)
fenofibrate
CAPSULE;ORAL019304-004Jun 30, 1999DISCNNo► subscribe► subscribe
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 2001DISCNNo6,277,405► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbott
TRICOR
fenofibrate
TABLET;ORAL021203-001Sep 4, 20014,895,726► subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-002Nov 5, 20045,145,684► subscribe
Abbvie
TRICOR
fenofibrate
TABLET;ORAL021656-001Nov 5, 20045,145,684► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TRICOR

Drugname Dosage Strength RLD Submissiondate
fenofibrateTablets48 mgTricor7/1/2008
fenofibrateTablets145 mgTricor10/19/2007

Non-Orange Book Patents for Tradename: TRICOR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,124,057Propellant-based nanoparticulate dry powder aerosols and method of making► subscribe
8,652,464Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer► subscribe
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TRICOR

Country Document Number Estimated Expiration
Japan4831965► subscribe
World Intellectual Property Organization (WIPO)0126635► subscribe
Germany29825080► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc